Executives of a small biotech must feel some trepidation when forced to watch from the sidelines while their firm's pharma partner – the party often bringing the bulk of the financial backing, as well as the development and commercialization muscle, to the table – becomes itself the subject of an acquisition, a move that could result in reprioritization and termination of a once potentially lucrative collaboration.